Skip to main content
OpenTrials
Completed

NCT Number: NCT06930222

The Investigation of Predicting Mortality and Morbidity in Patients Admitted to Intensive Care Unit With Thoracic Trauma Using Selected Biomarkers and Parameters

This prospective study aimed to predict morbidity and mortality after thoracic trauma in intensive care unit evaluated clinical and biochemical data of 50 intensive care unit patients. The research examined demographic factors such as gender, age, and smoking status, trauma scoring systems like ISS and RTS as well as biomarkers such as Surfactant-d and oxygenation parameters including the ROX index, PaO₂/FiO₂ ratio and FiO₂.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Thorax Traumas

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Suleyman Demirel University

Isparta, 32260, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with thoracic trauma between the ages of 18-85
  • Patients who have been monitored in intensive care for at least 1 week

Exclusion criteria

  • Being outside the age range of 18-85
  • Pregnant patients
  • Patients whose intensive care follow-up lasted less than 1 week
  • Patients who do not want to be included in the study
  • Patients with a lung malignancy diagnosis before admission

Treatment and study plan

Blood sampling

Diagnostic Test

blood samples obtained for 3 different days, limited to 5cc

Primary outcomes

  1. Mortality Prediction Using ROX Index in Thoracic Trauma Patients

    Time frame: Measurements taken on day 1, day 3, and day 7 of hospitalization, following ICU admission.

    To evaluate the predictive ability of the ROX index (unit: cmH₂O/L/s) for mortality in thoracic trauma patients. ROX index values were recorded at 1st, 3rd, and 7th days of hospitalization using standard clinical monitoring and ventilatory support parameters. Trends were analyzed in relation to survival outcomes.

  2. Mortality Prediction Using SP-D Levels in Thoracic Trauma Patients

    Time frame: Measurements taken on day 1, day 3, and day 7 of hospitalization, following ICU admission.

    To assess the prognostic value of Surfactant Protein D (SP-D) levels (unit: ng/mL) for mortality prediction in thoracic trauma patients. SP-D levels were measured using an ELISA assay (Elabscience® Human Pulmonary Surfactant-associated Protein-D ELISA Kit) at 1st, 3rd, and 7th days to evaluate trends and correlations with survival outcomes.

Secondary outcomes

  1. Predictive Value of APACHE II Score in Mortality

    Time frame: Measurements taken on day 1, day 3, and day 7 of hospitalization.

    To analyze the effectiveness of the APACHE II score (range: 0-71; higher scores indicate worse outcomes) in predicting mortality in thoracic trauma patients. APACHE II scores were calculated based on clinical and laboratory parameters, including vital signs, blood gas values, and organ dysfunction markers at 1st, 3rd, and 7th days.

  2. Predictive Value of SOFA Score in Mortality

    Time frame: Measurements taken on day 1, day 3, and day 7 of hospitalization.

    To evaluate the prognostic accuracy of the Sequential Organ Failure Assessment (SOFA) score (range: 0-24; higher scores indicate worse outcomes) in thoracic trauma patients. SOFA scores were determined based on respiratory, cardiovascular, hepatic, coagulation, renal, and neurological functions at 1st, 3rd, and 7th days.

  3. Predictive Value of TRISS Score in Mortality

    Time frame: Measurements taken on day 1, day 3, and day 7 of hospitalization.

    To examine the relationship between Trauma and Injury Severity Score (TRISS) (range: 0-100%; higher scores indicate better survival probability) and survival outcomes in thoracic trauma patients. TRISS scores were calculated using physiological and anatomical injury severity data at 1st, 3rd, and 7th days.

  4. Predictive Value of RTS Score in Mortality

    Time frame: Measurements taken on day 1, day 3, and day 7 of hospitalization.

    To assess the relationship between Revised Trauma Score (RTS) (range: 0-7.84; higher scores indicate better prognosis) and mortality risk in thoracic trauma patients. RTS scores were calculated using Glasgow Coma Scale, systolic blood pressure, and respiratory rate values at 1st, 3rd, and 7th days.

  5. CRP Levels and Mortality Prediction

    Time frame: Measurements taken on day 1, day 3, and day 7 of hospitalization.

    To evaluate the association between C-reactive protein (CRP) levels (unit: mg/L) and mortality in thoracic trauma patients.

  6. Procalcitonin Levels and Mortality Prediction

    Time frame: Measurements taken on day 1, day 3, and day 7 of hospitalization.

    To analyze the prognostic value of procalcitonin (unit: ng/mL) levels in mortality prediction among thoracic trauma patients.

Other outcomes

  1. NEU/LYM Ratio and Mortality Correlation

    Time frame: Measurements taken on day 1, day 3, and day 7 of hospitalization.

    To investigate the prognostic role of the Neutrophil-to-Lymphocyte Ratio (NEU/LYM) (unit: ratio value) in predicting mortality among thoracic trauma patients. NEU/LYM values were obtained from complete blood count (CBC) results and recorded at 1st, 3rd, and 7th days

  2. Glasgow Coma Scale (GCS) and Mortality Correlation

    Time frame: Measurements taken on day 1, day 3, and day 7 of hospitalization.

    Description: To evaluate the predictive value of the Glasgow Coma Scale (GCS) score on mortality and other clinical outcomes in thoracic trauma patients.

    Score Range: 3-15 (lower scores indicate worse outcomes).

Sponsors and collaborators

Lead sponsor

Suleyman Demirel University

Other

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Apr 16, 2025
Registry last updated
Apr 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.